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Abstract
Objective To examine the cost and cost effectiveness of quarterly CD4
cell count and viral load monitoring among patients taking antiretroviral
therapy (ART).
Design Cost effectiveness study.
Setting A randomised trial in a home based ART programme in Tororo,
Uganda.
Participants People with HIV who were members of the AIDS Support
Organisation and had CD4 cell counts <250 ×10
6 cells/L or World Health
Organization stage 3 or 4 disease.
Main outcome measures Outcomes calculated for the study period
and projected 15 years into the future included costs, disability adjusted
life years (DALYs), and incremental cost effectiveness ratios (ICER; $
per DALY averted). Cost inputs were based on the trial and other
sources. Clinical inputs derived from the trial; in the base case, we
assumed that point estimates reflected true differences even if
non-significant. We conducted univariate and multivariate sensitivity
analyses.
Interventions Three monitoring strategies: clinical monitoring with
quarterly CD4 cell counts and viral load measurement (clinical/CD4/viral
load); clinical monitoring and quarterly CD4 counts (clinical/CD4); and
clinical monitoring alone.
Results With the intention to treat (ITT) results per 100 individuals
starting ART, we found that clinical/CD4 monitoring compared with
clinical monitoring alone increases costs by $20 458 (£12 780, €14 707)
and averts 117.3 DALYs (ICER=$174 per DALY). Clinical/CD4/viral load
monitoring compared with clinical/CD4 monitoring adds $142 458, and
averts 27.5 DALYs ($5181 per DALY). The superior ICER for clinical/CD4
monitoring is robust to uncertainties in input values, and that strategy is
dominant (less expensive and more effective) compared with
clinical/CD4/viral load monitoring in one quarter of simulations. If clinical
inputs are based on the as treated analysis starting at 90 days (after
laboratory monitoring was initiated), then clinical/CD4/viral load
monitoring is dominated by other strategies.
Conclusions Based on this trial, compared with clinical monitoring alone,
monitoring of routine CD4 cell count is considerably more cost effective
than additionally including routine viral load testing in the monitoring
strategy and is more cost effective than ART.
Introduction
Antiretroviral therapy (ART) offers benefits for patients with
HIVinresourcepoorcountriesthataresimilartothosereported
from industrialised countries. These include reductions in viral
load, increases in CD4 cell count, reduced incidence of
opportunisticinfections,decreasedmortality,andimprovements
in wellbeing and functioning.
1 2
In response to worldwide demand and increased funding,
implementationofARTisproceedingrapidlyinthedeveloping
world, particularly in sub-Saharan Africa.
1 The expansion of
bothtreatmentandpreventionactivitiesisamajordevelopment
in the global response to HIV/AIDS, and provision of ART is
a unique global expansion of resource intensive disease
management. A three year home based ART trial in rural
Uganda showed the feasibility of achieving excellent health
outcomes in a rural African setting.
2 National and provincial
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Research
RESEARCHART programmes in Malawi, Zambia, South Africa, and
elsewhere have shown the capacity to provide high quality and
clinicallyeffectiveARTservicesonalargescale.
3 4 5Inaddition
to immediate health benefits, ART provides an opportunity for
long term enhancement of the capacity of health systems.
Thesebenefitsandopportunitiesnotwithstanding,theinvestment
in ART represents an opportunity cost compared with other
possible uses of funds to promote global health. Recent global
economicchangeshaveresultedinlevelorreducedfundingfor
HIVpreventionandcareinternationally,evenwithanincreasing
number of people affected.
1 In addition, the ultimate benefits
of spending on ART depend on the choices concerning drugs,
technology, and care of patients that can alter its cost
effectiveness profile. These include choice of ART drug
regimens, work forces for carrying out various aspects of care,
and criteria for initiation of treatment and changing drugs.
Among the most important of these choices is the method for
monitoring the progression of disease in patients and their
responsetotreatment.Thethreemainapproachesaremonitoring
clinicalsignsandsymptoms;addinglaboratorymeasuresofCD
cell count to clinical observation; and adding viral load testing
totheothertwomethods.Thesemethodsaresuccessivelymore
costly but might be associated with better clinical outcomes.
An important question for policy regarding ART treatment is
whether laboratory monitoring yields superior outcomes, and,
if so, are these benefits large enough to justify the higher costs.
Routine monitoring of viral load and CD4 cell count during
ART were adopted in high income countries without studies
indicating improved survival compared with careful clinical
monitoring.Onemathematicalmodelforresourcepoorsettings
showed little benefit and considerable cost from routine
monitoring of viral load or CD4 cell count during 20 years of
follow-up.
6 Programmes in Haiti
7 and Malawi
8 have reported
treatmentsuccesswithclinicalmonitoringalone,althoughthey
lacked comparison with laboratory monitoring. The recent
DART trial found favourable results for clinical monitoring
over five years of follow-up.
9 By reducing routine laboratory
monitoring,thereispotentialforincreasingthenumberofpeople
who could be treated. Such reduction, however, could also lead
to premature or delayed changes to second line treatment, more
antiretroviral resistance, or increased morbidity.
Previous analyses on the cost effectiveness of different
monitoring strategies for ART were based on mathematical
models and assumed benefits and suggested a wide range in
costeffectiveness.
10Weconductedacosteffectivenessanalysis
of quarterly laboratory monitoring options for ART, based on
data from a randomised efficacy trial in Uganda.
11 Specifically,
we assessed the incremental costs, health gains (disability
adjusted life years (DALYs) averted), and cost per DALY
averted of adding CD4 counts to clinical monitoring and of
addingviralloadtestingtoCD4countsandclinicalmonitoring.
Methods
Setting
Tororo District in eastern Uganda has a population of 403 000,
of whom 91% live in rural areas and 46% are unable to meet
theirenergyrequirements(UgandaBureauofStatistics,National
Household Survey). Most people (80%) earn their living by
farming.Theannualpopulationgrowthrateis2.7%.
12 13In2005,
the prevalence of HIV in adults in this area of Uganda was
5.3%.
14
Patients and methods
We conducted two sequential studies among adults with HIV
who were clients of the AIDS Support Organization (TASO)
in Tororo and Busia Districts, Uganda.
11 The first study, started
in April 2001, followed participants for five months, then
provided daily cotrimoxazole prophylaxis and continued
follow-up for an additional 1.5 years. For the second study, we
enrolled all clinically eligible participants from the first study
and additional participants to achieve a total of 1045 people
taking ART.
2 This is referred to as the Home-Based AIDS Care
(HBAC) programme.
Households were visited weekly by lay providers who
re-supplied drugs and administered a standard symptom
questionnaire.Afterenrolment,participantshadnoroutineclinic
visits but were encouraged to come to the clinic or hospital for
signs and symptoms of toxicity or illness and were taken to the
clinic if they had certain defined symptoms. Participants were
randomly assigned to three different monitoring regimens:
clinical/CD4/viralload(quarterlyHIVviralloadsandCD4cell
counts, and weekly home visits), clinical/CD4 (quarterly CD4
cell counts and home visits), and clinical (visits alone).
11 No
other laboratory testing was routinely conducted during
follow-up,andserumchemistrieswereavailableonlyjustbefore
participants started taking ART. Adherence, as measured by
pillcounts,wasexcellent,withonly0.7-2.6%ofpatientstaking
lessthan95%ofpillscorrectlyinanycalendarquarter.
15Specific
ART regimens are described below.
Overview of analytical methods
We created a spreadsheet based cost effectiveness model to
comparethethreeARTmonitoringoptionsduringandafterthe
trial described above. Data for health parameters were derived
from the trial.
11 Intervention costs (monitoring tests and other
healthcare) were derived from the trial and other analyses.
16
Outcomescalculatedper100individualsstartingARTincluded
costs and DALYs (derived from mortality and morbidity rates)
over 15 years. We calculated cost effectiveness ratios as $ per
DALYaverted,incrementallybetweenstrategies.Weconducted
univariate and multivariate sensitivity analyses.
Cost effectiveness model
Our model was designed to assess the cost and health value of
each incremental use of resources for ART monitoring. This
incremental cost effectiveness ratio (ICER) is the difference in
costbetweentwomonitoringoptions,dividedbythedifference
in DALYs averted. We compared each monitoring option with
the next less expensive alternative. The clinical option was the
leastexpensive,followedbyclinical/CD4,andclinical/CD4/viral
load. We did not calculate cost effectiveness of
clinical/CD4/viral load monitoring compared with clinical
monitoring as this would numerically blend the two laboratory
monitoringstrategiesandthusobscuretheirindependentvalue.
The increase in costs between monitoring options reflects
differences in costs per person year for the monitoring tests
themselves (that is, CD4 and viral load); differences in costs of
antiretroviralregimens(becauseofunequalratesofprogression
to more costly second line treatment); and outpatient and
inpatient care. These were estimated based on use during the
three years’ median follow-up during the trial. Mortality
influences total costs by affecting the number of person years
of care in each arm. We projected costs of future HIV care
associated with the lives saved during the trial to a total of 15
years from start of treatment, using the observed arm specific
costs and rates of clinical outcomes during the trial.
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RESEARCHTheincreaseinhealthbenefits(thatis,DALYsaverted)between
monitoring options reflects differences in mortality, severe
morbidity, and the DALYs incurred with these clinical events.
Specifically:
DT=NDA×DD+Σ (NMA×DM)
whereDT=totalDALYsaverted;NDA=numberofdeathsaverted;
DD=DALYs averted per death averted; NMA=number of severe
morbid events averted; and DM=DALYs averted per morbid
event averted.
The DALYs from morbidity are summed across 14 diagnoses.
The DALYs associated with mortality are calculated for the
three year trial and then over the subsequent 12 years.
Data inputs
We relied mainly on data from the trial to determine the value
of health and intervention cost inputs,
11 16 17 supplemented by
published sources and expert opinion within the trial. Table 1
summarisesthedatainputs,⇓whicharediscussedbelowforthe
base case. Alternative input values and assumptions are
described for the sensitivity analyses.
Health inputs
Healtheventsforthebaselineanalysisreflectthetrial’sintention
to treat analyses. Point estimates for each monitoring strategy
are used, even if differences between study arms were not
significant at P=0.05. When multivariate analyses were
conducted in the trial, we calculated event rates reflecting the
adjusted differences between monitoring arms.
Deaths during the trial were most common in the clinical
monitoring arm (5.8 per 100 person years, adjusted), followed
by clinical/CD4 monitoring (4.1 per 100 person years, P=0.109
versusclinical),andclinical/CD4/viralloadmonitoring(3.7per
100personyears,P=0.698versusclinical/CD4).Severemorbid
events (without death) followed a similar pattern, though at
lower absolute rates.
Eachdeathwasestimatedtocause2.32DALYsduringthetrial,
representingtwoyearsoflostlifeonaverage(deathsweremore
common toward the start of the trial) and an age disability
weight of 1.16 given the average age in this cohort of 39. For
severe morbid events (14 different diagnoses), we multiplied
the rates in the trial by disability weights
18 and by duration
(estimated by project clinicians), yielding a wide range in
DALYs per event (0.019 to 0.75).
Future longevity and DALYs were modelled from trial
completion to 15 years by using arm specific annual mortality
rates from the trial. We estimated mean longevity during this
12 year period at 6.43 years (discounted) for clinical, 7.12 for
clinical/CD4, and 7.28 for clinical/CD4/viral load. The number
of DALYs per arm after the trial quantifies lost health from
mortality that occurs both during and after the trial.
Cost inputs
The cost of monitoring is predominantly in the consumable test
kit. For CD4 counts, the kit constitutes $3.80 (£2.40, €2.70) of
the total $4.68 unit cost and for viral load $27.20 of the total
$29.64. The remaining costs are capital, primarily for the test
machines, staff, and other costs—such as labelling stickers.
Rates of change of ART from first to second line treatment
affect the cost of monitoring strategies. From the trial, the rate
of change is highest for clinical (1.8% per year) and similar for
clinical/CD4 (0.4%) and clinical/CD4/viral load (0.7%). The
annual cost of treatment is $104 for first line ART (stavudine
150 mg, lamivudine 40 mg, and nevirapine 200 mg in a fixed
dose pill) and $995 for second line ART (tenofovir 300 mg,
didanosine 400 mg, and lopinavir 133.3 mg, and ritonavir 30
mg in a fixed dose pill).
19 Different antiretroviral treatment for
peoplecoinfectedwithtuberculosisandtheadditionofshipping
andotherancillarycostsraisestheaverageloadedregimencosts
for first and second line ART to $125 and $1119 a year,
respectively. Furthermore, the cost of first line treatment rises
overtime(2-4%permonth)becauseofchangesinantiretroviral
drugs within this regimen.
Table 1 also shows the costs per person year of use of health
services in the trial⇓. Differences across monitoring strategies
are highest for laboratory monitoring, reflecting quarterly
testing: $18.74 for CD4 and $137.30 for CD4 and viral load.
The cost of ART varies noticeably by monitoring strategy
because of large differences in regimen costs combined with
modest differences in change rates. Observed use of diagnostic
tests and treatment for opportunistic illnesses varied little
(despite sharply different morbidity rates; see sensitivity
analyses). Though inpatient costs were higher in the clinical
strategy, with daily costs of less than $5 (as is common in the
WHO CHOICE database for sub-Saharan Africa) the absolute
values are low.
16 17 20 Finally, differences in total costs of the
arms during the trial reflect differential mortality and thus
different total number of person years of receipt of ART.
We estimated the cost of future care of trial survivors based on
our simulations out to 15 years, incorporating the arm specific
mortalityandratesofchangeofantiretroviralregimensobserved
during the trial. The future cost per person alive after the trial
is $4976 (discounted) for clinical, $4892 for clinical/CD4, and
$6043 for clinical/CD4/viral load. Total costs for each arm
represent the product of cost per person and the number alive
of the original 100 in the arm.
Comparison with cotrimoxazole
We examined the cost effectiveness of ART overall and of the
least expensive ART arm (clinical monitoring) compared with
treatment with cotrimoxazole alone. This extends an earlier
analysis that compared the entire ART cohort at two years with
cotrimoxazole.
17Thecotrimoxazolecomparisonresultsarefrom
a different trial in the same population. We included this
comparison because some readers might be interested in the
cost effectiveness comparison of ART versus cotrimoxazole
alone,giventhatHIVcareresourcesareincreasinglyconstrained
in Africa and a decreasing proportion of people with HIV will
beabletoaccessART.Thus,theanalysisprovidescomparisons
in a cohort of people with HIV across the broad continuum of
care from cotrimoxazole to ART with clinical monitoring, to
ARTwithclinicalandlaboratorymonitoring.Wehaveincluded
only the clinical benefits to the patient (not prevention of HIV
transmission and other outcomes), so the results might not be
precisely comparable.
Sensitivity analyses
We examined the effect of uncertainty in inputs and modelling
assumptions on the ICERs. We varied individual parameter
values (such as the relative mortality across monitoring arms
andcostsofmonitoringtests),aswellasbroaderdecisions(such
as using intention to treat versus per protocol trial results, and
limiting the analysis to the trial period). We used Monte Carlo
simulations to portray the impact of simultaneous variation in
key inputs.
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RESEARCHResults
Base case
During the three year trial, the clinical strategy cost the least
($190 570 per 100 individuals starting the arm), followed by
clinical/CD4($194844),andclinical/CD4/viralload($229521)
(table 2⇓). The most important difference in cost across arms
was monitoring, with a smaller difference for antiretroviral
drugs.Totalcostsover15yearsfollowasimilarpattern,at$606
260, $626 718, and $769 177, respectively. The difference in
total costs was $20 458 for clinical/CD4 versus clinical and
$142458forclinical/CD4/viralloadversusclinical/CD4(table
3⇓).
DALYs were determined almost entirely by mortality. During
the trial, the most deaths (17.5 per 100 individuals starting the
arm) and the most DALYs (44.4 per 100 individuals starting
the arm, including 40.5 deaths) occurred in the clinical strategy
arm. The figures for DALYs were 30.5 (28.3 deaths) in the
clinical/CD4armand27.1(25.8deaths)intheclinical/CD4/viral
loadarm.Afterthetrial,DALYscontinuedtoreflectdifferential
mortality by arm and were about 10 times higher than DALYs
incurred during the trial: 422.0, 318.6, and 294.5 for the three
arms,respectively.TheDALYtotalafterthetrialishighbecause
each death, whether during or after the trial, incurs DALYs in
each subsequent year. Total DALYs were 466.4 for clinical,
349.1 for clinical/CD4, and 321.6 for clinical/CD4/viral load.
The difference in estimated total DALYs was 117.3 for clinical
versus clinical/CD4 and 27.5 for clinical/CD4 versus
clinical/CD4/viral load (table 3).⇓
Table 3 shows incremental costs, health outcomes, and cost
effectiveness⇓.Theincrementalcomparisonsofinterest,guided
by the order of increasing cost, are clinical/CD4 versus clinical
and clinical/CD4/viral load versus clinical/CD4. For the base
case, each increase in cost is associated with increased health
benefits (that is, fewer DALYs incurred), so no strategy is
“dominated.”
The cost per DALY averted was $174 for clinical/CD4 versus
clinical and $5195 for clinical/CD4/viral load versus
clinical/CD4. The 30-fold higher ICER for the second
comparison is because of sevenfold higher incremental costs
and three quarters lower difference in DALYs.
Comparison with cotrimoxazole
The cost of a cotrimoxazole strategy was $9299 for 100
individuals over 15 years.
16 This reflects $50 per person year
and reduced survival (and thus person years of care) compared
withART.DALYsover15yearstotalto1160.Thus,compared
with cotrimoxazole, ART with clinical monitoring adds $596
961 and averts 693.7 DALYs for an ICER of $861 per DALY
averted. ART overall (all three arms combined) adds $658 086
and averts 781.1 DALYs for an ICER of $843 per DALY
averted. The second ICER is lower (by 2.1%) because of the
attractiveICERofgoingfromclinicaltoclinical/CD4.Asnoted
above, these ICERs consider only the clinical value to the
individual receiving treatment, omitting the health and cost
effects associated with prevention and other benefits of ART,
and thus are higher than the more inclusive ICERs below.
Implications for ART programming
We estimate $518 per DALY averted for ART with the
clinical/CD4 strategy versus cotrimoxazole, based on the
previous finding of $573 per DALY averted for ART (all arms)
versuscotrimoxazole
17andthelowerICERwhenCD4isadded
to clinical monitoring. We estimated $637 per DALY averted
for ART with clinical/CD4/viral load versus cotrimoxazole
because of higher monitoring and costs of antiretrovirals. If a
nationalprogrammehas$100milliontospendforART,amean
cost of $518 per DALY averted implies that 193 145 DALYs
could be averted. If instead, the same money was spent at $637
perDALYaverted,then156935DALYscouldbeaverted.The
differenceof36210DALYsrepresentsthepotentialhealthloss
of allocating programme funds to viral load testing instead of
startingmorepeopleonARTwithclinicalandCD4monitoring.
From the cost perspective, an additional $23 million would be
needed to include viral load testing with no change in DALYs.
Sensitivity analyses
Table 4 reports the effect on ICERs of variation in key inputs
and modelling assumptions⇓. We examined uncertainty in the
mortality rate as suggested by the 95% confidence intervals for
observedadjustedhazardratiosintheintentiontotreatanalysis.
For clinical/CD4/viral load, with the most favourable hazard
ratio and mortality rate, the ICER drops below $1600. With the
worstmortality,theclinical/CD4/viralloadstrategyisdominated
by clinical/CD4 (more expensive and less effective). For
clinical/CD4, lower mortality worsens the ICER because the
ICER approaches the cost effectiveness of keeping individuals
alive on ART (that is, cost and a year’s DALYs v death and no
cost). When mortality is higher, the clinical/CD4 arm becomes
less expensive and effective than clinical, so the ICER is
calculated in the reverse direction.
The trial’s per protocol (as treated) analysis examined only the
period after monitoring began (at 90 days), removing the early
period of high mortality unrelated to ART monitoring. This
analysis found adjusted mortality rates of 2.2, 2.0, and 3.5 per
100 patient years for the clinical/CD4/viral load, clinical/CD4,
and clinical arms, respectively. The clinical/CD4 arm had an
ICER of $88 per DALY averted compared with clinical alone,
and the viral load option was dominated compared with the
clinical/CD4 arm.
Varying the rate of change in regimen between 50% and 150%
ofbasecasevalues(forallarmssimultaneously)hadlittleeffect
ontheICERforviralload($4882-5466).Ithasaproportionately
larger effect on the ICER for CD4 versus clinical
($401-“dominant”). This is because of the small and similar
switch rates in clinical/CD4/viral load and clinical/CD4 arms
and the larger base case value of regimen switch rates in the
clinical arm.
When we limited the analysis to the trial period (instead of
estimating future DALYs averted and costs added), the ICER
forclinical/CD4versusclinicalwas$307,176%abovethebase
case value ($174). This difference reflects the lower long term
cost per person year on ART for clinical/CD4 (because of a
lower rate of change in antiretroviral regimen) than for clinical.
The ICER for viral load versus CD4 rose more sharply to $10
257, 198% above the base case value ($5181). This ICER is
more attractive after than during the trial for a different reason:
the increasing role in the analysis of the difference in person
years on ART (which has an ICER for this arm of about $600
per DALY).
The unit cost of monitoring test kits had more impact on the
ICER for viral load than for CD4. Halving the cost of CD4 test
kits decreased the ICER to $117 (67% of base case). When the
cost of the viral load test kit is reduced to 50% of its base case
value, the ICER for viral load decreases to $3 316 (64% of base
case). Doubling the cost increased the ICERs to $289 (166%
of base case) and $8911 (172% of base case) for CD4 and viral
load, respectively. The figure⇓ shows the same contrast in
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RESEARCHsensitivity for the range from one third to three times the base
case unit cost.
The cost of antiretroviral drugs has the expected effects on the
ICERs.TheICERforclinical/CD4versusclinicalismuchmore
affected than the other ICER because of the large difference in
rates of change in regimen between these arms. Lower costs of
first line regimens favour clinical/CD4 over clinical (that is,
they lower the ICER), as do higher costs of second line
regimens.
Whenwereplacedobservedcostsfortreatmentofopportunistic
infections(drugsandvisits;nearlyequalacrossarms)withcosts
forced to be proportional to observed opportunistic infections
rates, the ICER decreased to $1 for CD4 monitoring and
increased to $4906 for viral load monitoring.
We used a 50 000 trial Monte Carlo simulation (Crystal Ball
7.3, Denver, CO) to assess the aggregate uncertainty from all
varied inputs in the intention to treat analysis. In the absence of
information about the distribution of input values, we fitted β
distributions, with maximum and minimum values set to 50%
and 150% of the base case value, around each variable of
interest. The α and β parameters were set to three, ensuring a
symmetrical distribution approximating the normal with the
basecaseasthemeanvalue.
21Theonlyexceptionwasmortality
for the CD4 arm (which had a range corresponding to the 95%
confidence interval of the hazard ratio). The other variables
included in the simulation were the discount rate, the cost of
laboratory tests, the annual rate of regimen changes, and the
costs of first line and second line antiretroviral drugs. First line
and second line drug costs were correlated at 0.50. We found
that clinical/CD4 had an ICER between “dominant” and $421
per DALY averted (95% confidence interval), and is less than
$0 (dominates clinical) in 24.2% of trials. Clinical/CD4/viral
load had an ICER between less than $0 per DALY averted
(dominated) and $43 479 (95% confidence interval).
Clinical/CD4/viralloadisdominatedbyCD4in27.7%oftrials.
Discussion
Summary of findings
This analysis of the cost effectiveness of ART monitoring
strategies in Africa, which uses empirical data from an ART
monitoring trial, found that adding routine monitoring of CD4
cell counts to clinical monitoring was more cost effective than
the further addition of viral load monitoring. Adding CD4 cell
count to clinical monitoring at $174 per DALY averted was
more efficient than putting an additional person on ART in the
same setting ($573 per DALY
17). Adding viral load to clinical
and CD4 monitoring had a cost per DALY averted of
$5168—that is, nearly 10 times higher. Sensitivity analyses
suggested that viral load testing could cost up to $14 000 per
DALYavertedandhada25%chanceofbeingdominated—that
is, of being both more expensive and less effective than CD4
monitoring—because of substantially overlapping confidence
intervalsforclinicaloutcomesinthedifferentmonitoringarms.
Whenweusedtheastreated(perprotocol)resultsfromthetrial,
theclinical/CD4/viralloadarmwasdominatedbyclinical/CD4.
Thus, our analysis suggests that both CD4 monitoring and
starting a patient on ART are economically preferable to
monitoring viral load.
These findings are within the range of modelled cost
effectivenessofARTmonitoringinAfrica.
10 22TheDARTstudy,
the only other randomised controlled trial of ART monitoring
inAfrica,foundimprovedclinicaloutcomeswithCD4compared
with clinical monitoring after two years’ receipt of ART. The
estimated cost effectiveness ratio, however, was above $1200
perDALYaverted(exactvaluenotreported)becauseofahigher
switching rate to more expensive second line antiretroviral
regimens.
9 In our study, regimen switching was less common
with CD4 monitoring. The higher change rate for the clinical
arm was unexpected. However, it makes sense considering that
in the clinical monitoring arm, for participants with symptoms
potentiallyindicatingfailureofART(suchasaneworrecurrent
CDC category C condition, chronic diarrhoea, or candidiasis),
clinicianslackedaccesstomonitoringtodetectwhetherpatients
were immunologically responding to treatment or were
virologicallysuppressed.Thisprobablyincreasedthefrequency
ofdrugswitching.Bycontrast,intheclinical/CD4arm,patients
with a clinical event that indicated consideration for switching
could be retained on first line treatment if their CD4 cell count
remained high. Details of the clinical monitoring and regimen
change protocols are included in the report of the randomised
controlled trial.
11
Limitations
There are important limitations to our study. We treated
mortalitycomparisons,whichdominateourmodel’shealthand
cost effects, as meaningful regardless of statistical significance.
Thus, the base case results reflect observed differences in
mortality that were small and not quite significant for
clinical/CD4 versus clinical monitoring (combined mortality
and AIDS defined events were significantly different) and far
fromsignificantforclinical/CD4/viralloadversusclinical/CD4
monitoring . As a result, they could be considered overly
optimistic. Despite this lenient approach (counting as real a
difference for which there is little evidence), viral load had a
highly unfavourable ICER. Our sensitivity analyses highlight
how the uncertainty about these comparisons contributes to a
substantial likelihood that viral load monitoring is dominated.
Furthermore, in the per protocol analysis, which is arguably
appropriate for an intervention that starts three months after the
initiation of treatment, the clinical/CD4/viral load arm had a
mortality point estimate slightly higher than the clinical/CD4
arm.
We lacked data on mortality rates beyond the trial. To calculate
long range ICERs, we assumed ongoing arm specific mortality
ratesasobservedinthetrial.Theassumptionofhigherorlower
rates after the trial, however, did not change our findings
qualitatively—that is, clinical/CD4 monitoring retained its
superior cost effectiveness. Specifically, lower long term
mortality, as observed late in the trial, led to a more attractive
ICER for clinical/CD4 versus clinical monitoring, and higher
mortality increases the ICER just 50%. Within trial ICERs
generate similar results. Thus, our findings seem robust to
uncertainties in mortality.
This trial had high levels of adherence to ART, low rates of
virological failure, low rates of regimen switching, and low
mortality.Adherencewassimilartothehighestlevelsobserved
inAfricansettings.
23Also,adherencewashigherandvirological
failure was lower than observed in another recent Ugandan
trial.
24 This limits the generalisability of our study as we could
not explore the role of viral load monitoring in the context of
high short or long term failure of suppression of viral load. The
economic implications of lower adherence are uncertain as the
clinical/CD4 arm in our study was efficient in guiding regimen
change while improving clinical outcomes. In our sensitivity
analyses, higher overall rates of regimen change led to the
clinical/CD4 arm being dominant (lower cost and better
outcomes) by magnifying these favourable empirical trial
findings. In addition, in settings with low adherence, it might
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RESEARCHbe more cost effective to implement low cost adherence
interventions such as counselling and pill counts before viral
load testing. Direct study of the unique contribution and cost
of viral load monitoring in less adherent populations would be
extremely valuable (after reasonable measures to increase
adherence) and should include resistance testing.
The study had a home based component and was thus
structurally atypical. The relative cost effectiveness among
groups, however, is likely to be similar to facility based
programmesastheoverallcosteffectivenessofARTwassimilar
to facility based analyses in the Côte d’Ivoire and South
Africa.
25 26 In addition, all three strategies used quarterly
monitoring. In some countries, governments promote biannual
monitoring. Results for less frequent monitoring might differ
from ours.
We did not examine the benefits of ART in preventing HIV
transmission. In settings where viral load monitoring improves
ratesoffullviralsuppression,therewouldprobablybebenefits.
These might not be as great as initially assumed as the effect of
reduced viral load on HIV transmission is not dichotomous;
even a plasma viral load of 5000-10 000 copies/mL would
reducetheriskoftransmissionconsiderablycomparedwith500
000 copies/mL. Thus, the effect of identifying relatively slight
increases in viral load a few weeks or months earlier could be
less important than efforts to increase access to ART and
retention in care.
We did not assess all plausible configurations of laboratory
monitoring. For example, a strategy including clinical and
virological but not CD4 monitoring could potentially reduce
costs while detecting virological failure early. Viral load might
be a better indicator than CD4 cell counts of treatment success
andthusclinicallyadvantageous.Yetourstudydidnotindicate
improved efficacy from adding viral load to CD4 monitoring.
Furthermore, logistical challenges to viral load monitoring are
substantialinAfrica.CD4cellcountsaremorewidelyavailable
in peripheral health centres because of lower costs, ease of
operation and maintenance, and use for determining eligibility
for ART. Reliance on viral load could potentially work with
efficient referral to a central laboratory or new technology, but
currently in Uganda, routine viral load monitoring is unlikely
to be feasible outside a research setting or major cities. As less
expensive and logistically simpler viral load testing becomes
available,astudycomparingroutineCD4cellcountmonitoring
with routine viral load monitoring alone would be valuable.
Implications
Standards in clinical practice well attuned to resource rich
settings might not maximise the opportunities available in
resourceconstrainedsettings.MonitoringCD4cellcountsseems
desirable clinically and economically in these settings. In
contrast, viral load monitoring might be a relatively poor
investment compared with offering ART to another person or
monitoring CD4 cell counts for those currently taking ART.
This approach supports current WHO guidelines.
27
According to WHO, the attractiveness of the ICER can be
determined by comparison with the country’s annual gross
domestic product per capita. An intervention with an ICER
belowtheannualgrossdomesticproductpercapitaisconsidered
“very cost effective.” An ICER below three times the annual
gross domestic product per capita is considered “cost
effective.”
28 The annual gross domestic product per capita in
Uganda in 2008 was an estimated 1200 international dollars
($485 using currency exchange rates).
13 Thus by the gross
domestic product per capita standard, CD4 count monitoring is
“very cost effective” and viral load monitoring is not cost
effective.
Inclosing,wewanttohighlightanotherpathtoincreasedaccess
to high quality ART in resource poor settings. We strongly
support efforts to reduce the price of second line antiretroviral
regimensandlaboratorytests.Ifsucheffortscouldreplicatethe
impressive past decreases in the price of first line regimens and
the also important reductions for CD4 counts, the types of
analyses reported here would be less necessary.
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RESEARCHTables
Table 1| Model data input values for cost effectiveness analysis, antiretroviral monitoring study, Tororo and Busia Districts, Uganda,
2003-7. All costs are in US $
Source(s)
Base case value
Parameter Clinical Clinical/CD4 Clinical/CD4/viral load
Frequency of health events:
Trial
11 5.8 4.1 3.7 Deaths (per 100 person years)*
Trial
11 4.9 2.7 1.7 Severe morbid events (per 100 person year)*
Disability adjusted life years per clinical event during trial:
Trial,
11 Global Burden of Disease
18 2.32 Deaths
Global Burden of Disease,
18 expert opinion 0.019-0.75 Severe morbid events (range)
Unit costs of monitoring tests:
Downing (Clinton Fund); trial
11 — $4.68 $4.68 CD4
COBAS Amplicor; trial
11 — — $29.64 Viral load
Trial
11 1.8% 0.4% 0.7% % Change in antiretroviral drug regimen (annual)
Costs of use during trial (per person year):
Trial
11 $0 $18.74 $137.30 Laboratory monitoring of CD4s and viral loads
Trial,
11 Médecins Sans Frontières
19 $175 $156 $160 Antiretroviral drugs (discounted; observed mix of first and
second line regimens during trial)
Trial
11 $164 $168 $168 Diagnostic tests
Trial
11 $127 $123 $122 Opportunistic infection treatment including tuberculosis
(outpatient)
Trial
11 $2.87 $1.96 $2.05 Inpatient costs
*From intention to treat analysis, adjusted for multivariate regression findings (see text).
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RESEARCHTable 2| Cost and health outcomes by monitoring strategy (per 100 people starting each arm), for cost effectiveness analysis, antiretroviral
monitoring study, Tororo and Busia Districts, Uganda, 2003-7
Clinical Clinical/CD4 Clinical/CD4/viral load
Costs ($)
190 570 194 844 229 521 Total during trial (three years)
0 5164 38 142 Laboratory monitoring CD4 and viral load*
46 370 42 897 44 402 Antiretroviral drugs*
415 690 431 874 539 656 Total after trial
606 260 626 718 769 177 Total
Health outcomes
44.4 30.5 27.1 DALYs during trial
17.5 12.2 11.1 Deaths
40.5 28.3 25.8 DALYs from deaths
3.90 2.17 1.36 DALYs from opportunistic infections
422.0 318.6 294.5 Future DALYs
466.4 349.1 321.6 Total DALYs
*Selected cost detail presented to show major variation across strategy.
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RESEARCHTable 3| Incremental costs, DALYs, and cost effectiveness ratios for antiretroviral monitoring study, Tororo and Busia Districts, Uganda,
2003-7
ICER: $ per DALY averted Incremental DALYs averted DALYs incurred Incremental cost ($) Cost ($)
— — 466.4 — 606 260 Clinical
174 117.3 349.1 20 458 626 718 Clinical/CD4
5181 27.5 321.6 142 458 769 177 Clinical/CD4/viral load
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RESEARCHTable 4| Sensitivity analyses for key inputs and modelling assumptions for cost effectiveness analysis, antiretroviral monitoring study,
Tororo and Busia Districts, Uganda, 2003-7
Most/least favourable ICER ($/DALY averted) Values/methods used
Input or assumption
Clinical/CD4/viral load (v
clinical/CD4) Clinical/CD4 (v clinical) Most/least favourable* Base case
Deaths per 100 person years (intention to treat):
1550/dominated‡ 174/174 2.22/6.11 3.7 Clinical/CD4/viral load, 95% CI†,
other arms kept at base case
Dominated‡/1263 368/1792§ 2.55/6.48 4.1 Clinical/CD4, 95% CI†, other arms
kept at base case
5181/5181 454/2832§ 9.10/3.70 5.8 Clinical, 95% CI†, other arms kept
at base case
Deaths per 100 person years (per protocol):
NA/dominated‡ NA/88 NA/2.2, 2.0, 3.5 Intention to treat
(above)
Viral load arm, CD4 arm, clinical
arm
Annual rate of regimen change:
4882/5466 401/dominant‡ 50-150% of base case
values
0.7%, 0.4%, 1.8% Viral load arm, CD4 arm, clinical
arm
Future DALYs averted and costs added per death:
NA/10 257 NA/307 NA/excluded Included Inclusion or exclusion of projections
beyond trial
Unit costs of monitoring test kits:
5187/5175 233/115 1.90/5.70 3.80 CD4
3322/7040 176/173 13.60/54.40 27.20 Viral load
Costs of antiretroviral drugs (annual; per person):
5169/5193 73/275 63/188 125 First line regimen
4825/5538 451/dominant‡ 557/1679 1119 Second line regimen
Costs of opportunistic infection treatment:
4906/NA 1.06/NA 97, 123, 194/NA 122, 123, 127 Observed (base case) v imputed
from rates of opportunistic infection
NA=not applicable.
*For cost effectiveness of laboratory testing.
†95% CI from clinical trial.
11
‡Dominated=higher cost and fewer DALYs than comparator; dominant=cheaper and better.
§ICER for high end of mortality range represents reverse comparison among arms.
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RESEARCHFigure
Sensitivity analysis: price of test kits for cost effectiveness analysis, antiretroviral monitoring study, Tororo and Busia
Districts, Uganda, 2003-7
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